BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 21747412)

  • 1. Methotrexate consolidation treatment according to pharmacogenetics of MTHFR ameliorates event-free survival in childhood acute lymphoblastic leukaemia.
    Salazar J; Altés A; del Río E; Estella J; Rives S; Tasso M; Navajas A; Molina J; Villa M; Vivanco JL; Torrent M; Baiget M; Badell I
    Pharmacogenomics J; 2012 Oct; 12(5):379-85. PubMed ID: 21747412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methotrexate toxicity and efficacy during the consolidation phase in paediatric acute lymphoblastic leukaemia and MTHFR polymorphisms as pharmacogenetic determinants.
    D'Angelo V; Ramaglia M; Iannotta A; Crisci S; Indolfi P; Francese M; Affinita MC; Pecoraro G; Napolitano A; Fusco C; Oreste M; Indolfi C; Casale F
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1339-46. PubMed ID: 21590445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MTHFR 677 (C-->T) polymorphism is not relevant for prognosis or therapy-associated toxicity in pediatric NHL: results from 484 patients of multicenter trial NHL-BFM 95.
    Seidemann K; Book M; Zimmermann M; Meyer U; Welte K; Stanulla M; Reiter A
    Ann Hematol; 2006 May; 85(5):291-300. PubMed ID: 16463153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High dose methotrexate treatment in childhood ALL: pilot study on the impact of the MTHFR 677C>T and 1298A>C polymorphisms on MTX-related toxicity.
    Haase R; Elsner K; Merkel N; Stiefel M; Mauz-Körholz C; Kramm CM; Körholz D
    Klin Padiatr; 2012 Apr; 224(3):156-9. PubMed ID: 22513795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia.
    Csordas K; Lautner-Csorba O; Semsei AF; Harnos A; Hegyi M; Erdelyi DJ; Eipel OT; Szalai C; Kovacs GT
    Br J Haematol; 2014 Aug; 166(3):410-20. PubMed ID: 24712521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of plasma methotrexate level and MTHFR genotype in Korean paediatric patients with acute lymphoblastic leukaemia.
    Chae H; Kim M; Choi SH; Kim SK; Lee JW; Chung NG; Cho B; Kim Y
    J Chemother; 2020 Sep; 32(5):251-259. PubMed ID: 32431230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of MTHFR C677T polymorphism and plasma pharmacokinetics to predict methotrexate toxicity in patients with acute lymphoblastic leukemia.
    Mahmoud LB; Mdhaffar M; Frikha R; Ghozzi H; Hakim A; Sahnoun Z; Elloumi M; Zeghal K
    Adv Clin Exp Med; 2018 Aug; 27(8):1061-1068. PubMed ID: 29911750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C677T and A1298C polymorphisms of the methylenetetrahydrofolate reductase gene: effect on methotrexate-related toxicity in adult acute lymphoblastic leukaemia.
    Eissa DS; Ahmed TM
    Blood Coagul Fibrinolysis; 2013 Mar; 24(2):181-8. PubMed ID: 23183238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methotrexate-induced mucositis in acute leukemia patients is not associated with the MTHFR 677T allele in Mexico.
    Ruiz-Argüelles GJ; Coconi-Linares LN; Garcés-Eisele J; Reyes-Núñez V
    Hematology; 2007 Oct; 12(5):387-91. PubMed ID: 17891601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Relationship between the methylenetetrahydrofolate reductase gene polymorphism and adverse reactions of high-dose methotrexate in children with acute lymphocytic leukemia].
    Zheng MM; Yue LJ; Chen XW; Wen FQ; Li CG; Yang CL; Xie C; Ding H
    Zhongguo Dang Dai Er Ke Za Zhi; 2013 Mar; 15(3):201-6. PubMed ID: 23498762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
    Joannon P; Oviedo I; Campbell M; Tordecilla J
    Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of pre-hydration and pharmacogenetics on plasma methotrexate concentration and renal dysfunction following high-dose methotrexate therapy.
    Yanagimachi M; Goto H; Kaneko T; Naruto T; Sasaki K; Takeuchi M; Tanoshima R; Kato H; Yokosuka T; Kajiwara R; Fujii H; Tanaka F; Goto S; Takahashi H; Mori M; Kai S; Yokota S
    Int J Hematol; 2013 Dec; 98(6):702-7. PubMed ID: 24241962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of folate pathway polymorphisms on high-dose methotrexate-related toxicity and survival in childhood acute lymphoblastic leukemia.
    Erčulj N; Kotnik BF; Debeljak M; Jazbec J; Dolžan V
    Leuk Lymphoma; 2012 Jun; 53(6):1096-104. PubMed ID: 22074251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MTHFR polymorphisms' influence on outcome and toxicity in acute lymphoblastic leukemia patients.
    Chiusolo P; Reddiconto G; Farina G; Mannocci A; Fiorini A; Palladino M; La Torre G; Fianchi L; Sorà F; Laurenti L; Leone G; Sica S
    Leuk Res; 2007 Dec; 31(12):1669-74. PubMed ID: 17512587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional variants of gene encoding folate metabolizing enzyme and methotrexate-related toxicity in children with acute lymphoblastic leukemia.
    Kałużna E; Strauss E; Zając-Spychała O; Gowin E; Świątek-Kościelna B; Nowak J; Fichna M; Mańkowski P; Januszkiewicz-Lewandowska D
    Eur J Pharmacol; 2015 Dec; 769():93-9. PubMed ID: 26528799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of methylene tetrahydrofolate reductase polymorphisms and coadministration of antimetabolites on toxicity after high dose methotrexate.
    van Kooten Niekerk PB; Schmiegelow K; Schroeder H
    Eur J Haematol; 2008 Nov; 81(5):391-8. PubMed ID: 18691257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue.
    Chiusolo P; Giammarco S; Bellesi S; Metafuni E; Piccirillo N; De Ritis D; Marietti S; Federica S; Laurenti L; Fianchi L; Hohaus S; Giuseppe L; Sica S
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):691-6. PubMed ID: 21984221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of the pharmacokinetic and pharmacogenetic contribution to the toxicity of high-dose methotrexate in children with acute lymphoblastic leukemia.
    El-Khodary NM; El-Haggar SM; Eid MA; Ebeid EN
    Med Oncol; 2012 Sep; 29(3):2053-62. PubMed ID: 21644011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of CNS recurrence in childhood ALL: results with reduced radiotherapy combined with CNS-directed chemotherapy in four consecutive ALL-BFM trials.
    Schrappe M; Reiter A; Henze G; Niemeyer C; Bode U; Kühl J; Gadner H; Havers W; Plüss H; Kornhuber B; Zintl F; Ritter J; Urban C; Niethammer D; Riehm H
    Klin Padiatr; 1998; 210(4):192-9. PubMed ID: 9743952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma.
    Faganel Kotnik B; Grabnar I; Bohanec Grabar P; Dolžan V; Jazbec J
    Eur J Clin Pharmacol; 2011 Oct; 67(10):993-1006. PubMed ID: 21509569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.